Marsha L Frazier

Title: Marsha L Frazier: Innovator in Cancer Research

Introduction

Marsha L Frazier is a prominent inventor based in Houston, TX (US). She has made significant contributions to the field of cancer research, particularly in developing methods to combat drug resistance in cancer therapies. With a total of 2 patents, her work has the potential to impact treatment options for patients suffering from gastrointestinal stromal tumors and other cancers.

Latest Patents

One of her latest patents is titled "Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors." This invention relates to methods and compositions that address resistance to cancer drugs, specifically those involving aberrant KIT signaling. The patent highlights a specific mutation in a KIT polynucleotide that confers resistance to imatinib treatment, providing a means to adjust for or circumvent this resistance.

Another notable patent is "Metalocarboxypeptidase inhibitors and derived molecules used as antitumor agents." This invention focuses on metalocarboxypeptidase inhibitors and their natural protein variants, as well as engineered variants and peptidomimetic molecules that serve as antitumor agents.

Career Highlights

Marsha has worked with the University of Texas System, where she has contributed to various research initiatives. Her work has been instrumental in advancing the understanding of cancer treatment and drug resistance.

Collaborations

Throughout her career, Marsha has collaborated with notable colleagues, including Lei L Chen and Rafael De Llorens Duran. These partnerships have enhanced her research and contributed to her innovative patents.

Conclusion

Marsha L Frazier's contributions to cancer research through her patents demonstrate her commitment to improving treatment options for patients. Her innovative work continues to pave the way for advancements in the field of oncology.